Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 0 trial of Alt-100 for treatment of Adult respiratory distress syndrome

Next Previous
X
Search
Trial Profile

Phase 0 trial of Alt-100 for treatment of Adult respiratory distress syndrome

Status: Planning
Phase of Trial: Phase 0

Latest Information Update: 24 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALT 100 (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Adverse reactions
  • Sponsors Aqualung Therapeutics

    • Most Recent Events

    • 24 Jun 2021 New trial record
    • 15 Jun 2021 according to an Aqualung Therapeutics Corp media release, The company completed a successful Type B meeting with the U.S. Food and Drug Administration (FDA).
    • 15 Jun 2021 According to an Aqualung Therapeutics Corp media release, The company is planning to move forward with a Phase 0 study in ARDS subjects in the coming months to be included as an important component of our IND submission packet. This phase 0 trial is an exploratory investigational new drug (IND) study,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top